Patent classifications
A61M1/3664
Reservoir assembly for providing cardioplegic solution containing bicarbonate ion, and method for manufacturing the same
The object of the invention is to provide a novel reservoir assembly for providing a cardioplegic solution and a method for manufacturing the same. An aspect of the invention is to provide a reservoir assembly for providing a cardioplegic solution, comprising a multi-chamber reservoir; a gas-impermeable outer package packaging the multi-chamber reservoir; an oxygen detection agent and a deoxygenation agent in a space part between the multi-chamber reservoir and the outer package, wherein the deoxygenation agent neither generates nor absorbs carbon dioxide, wherein the multi-chamber reservoir comprises at least a first chamber, a second chamber, and a first separator wall that separates the two chambers, the first chamber holds a first medical liquid, the second chamber holds a second medical liquid containing bicarbonate ions, one or both of the first medical liquid and the second medical liquid contains potassium ions, the cardioplegic solution comprises the first medical liquid and the second medical liquid, and the cardioplegic solution contains bicarbonate ions of 5 to 20 mEq/L and potassium ions of 5 to 35 mEq/L. Another aspect of the invention is to provide a method for manufacturing the reservoir assembly for providing a cardioplegic solution.
MYOCARDIAL PROTECTION SYSTEM
An embodiment includes a cardioplegia delivery system having a console, controller, and disposables. The console, in conjunction with the disposables, combines blood from the heart-lung machine and crystalloid from the IV-bag in a specified ratio and then adds in a drug (arrest agent and/or additive). The electro-mechanical console incorporates a blood/crystalloid pump, temperature controllable water circulation system, pressure and temperature monitors, a sensor interface with the disposables, an arrest agent pump, an additive pump and ultra-sonic air detection sensors. The system monitors and controls the blood-crystalloid ratio, drug concentration, flow rate, pressure, temperature, and delivery route of the cardioplegia solution delivered to the patient. The system is a software-controlled system with a graphical user interface controller. The controller is utilized to initiate/stop cardioplegia delivery, monitor delivery parameters and view/save relevant case information and data.